Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
This pivotal study demonstrates that the combination of enfortumab vedotin and pembrolizumab not only extends progression-free survival but also significantly improves overall survival rates in patients with untreated advanced urothelial carcinoma.
Oncology, Medical March 11th 2024
The POLARIX trial reveals polatuzumab vedotin with R-CHP as a promising first-line therapy for DLBCL, showing a 27% reduction in the risk of progression, relapse, or death and a progression-free survival rate of 76.7% at 2 years.
Hematology/Oncology February 12th 2024
NEJM Evidence
In a recent phase II trial, patients with untreated metastatic pancreatic ductal adenocarcinoma receiving sequential nab-P/Gem-mFOLFOX experienced a median overall survival of 13.2 months, compared to 9.7 months in those receiving standard nab-P/Gem treatment, indicating a notable improvement in survival outcomes.
Oncology, Medical February 5th 2024
Hematology Advisor
In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.
Hematology January 22nd 2024
DocWire News
In a recent study, researchers found that, although pembrolizumab increased the pathological complete response in gastric cancer patients, it did not significantly improve event-free survival.
Gastroenterology January 16th 2024
The study’s findings suggest that ibrutinib–venetoclax therapy could potentially revolutionize the treatment of CLL. With a significant reduction in disease progression or death at a median of 43.7 months, this therapy could offer a promising alternative to the standard FCR regimen.
Hematology/Oncology January 2nd 2024